Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting
– Company to host Key Opinion Leader webinar today, September 12, at 1:30 pm CT/2:30…